Roche's Oral SERD Giredestrant Fails Phase 3 persevERA Trial in First-Line Breast Cancer

Roche's oral SERD giredestrant plus palbociclib (Ibrance) failed to meet the primary endpoint of statistically significant progression-free survival (PFS) improvement versus letrozole plus palbociclib in the Phase 3 persevERA trial for ER-positive, HER2-negative locally advanced or metastatic breast cancer.1 2 3

A numerical improvement in PFS was observed, and adverse events were manageable and consistent with known profiles.1 2 4

The trial enrolled endocrine-sensitive first-line patients; another first-line trial, pionERA, in endocrine-resistant patients is expected in 2027.1 2

Giredestrant succeeded in Phase 3 evERA (second-line advanced) and lidERA (adjuvant early-stage) trials; FDA accepted NDA based on evERA, with lidERA submission planned soon.1 2 3

Failure raises questions on oral SERDs in first-line settings, impacting sales forecasts; Roche shares fell nearly 5%.2 5

Competitive landscape includes AstraZeneca's camizestrant (first-line win) and others like palazestrant.1 2